Page 1,652«..1020..1,6511,6521,6531,654..1,6601,670..»

Artificial blood: the quest for one of science’s holy grails – Stat – STAT

Posted: March 5, 2017 at 9:44 am

S

T. LOUIS When red blood cells are poured into the test tubes here in Dr. Allan Doctors lab, tiny tools measure the reaction of the rabbit aortas strung up inside, computing if and how strongly the aortas constrict. Doctor and his team are trying to make sure that when they dump in the artificial blood theyre developing, the aortas react the same way.

The experiments being conducted on a recent day were not only just a few of the many the team will need to run before testing their blood substitute in people, but were also early steps to show that their design, with any luck, can steer them beyond the decades of failure in the field.

There has been about 50, 60 years of research in trying to make a blood substitute that has not worked, said Doctor, a pediatric critical care physician and researcher at Washington University in St. Louis.

article continues after advertisement

The need for such a product is clear. Blood loss from traumatic injuries is responsible for thousands of deaths annually, and even when people survive, oxygen depletion can leave tissue permanently injured. Fresh blood can only be stored for 42 days, and only lasts for a few hours unrefrigerated. A substitute could be vital in settings like battlefields or rural areas without easy access to blood, used as a stopgap measure to keep the injured alive until they get to a hospital.

But the quest to develop substitute blood has bedeviled researchers in academia, the military, and the biopharma industry, with several companies including Baxter, Northfield Laboratories, and Biopure abandoning theirattempts.

The artificial blood researchers have been trying to cook up is not a true substitute, in that it wouldnt perform all of bloods functions, but rather provide a means to deliver oxygen throughout the body.

One key problem: Hemoglobin, the protein in red blood cells that carries oxygen from the lungs to needy tissues, can damage tissue and cause blood vessels to constrict. Thats one reason why hemoglobin is contained in cells to isolate it and its toxic iron.

Any successful blood substitute will need to transport and deliver oxygen, while staving off the threat hemoglobin poses.

In past attempts, scientists have tried to tweak hemoglobin to make it safer, but so far, no blood substitute has been approved for use in the United States or Europe. (One substitute, Hemopure from HbO2 Therapeutics, is used in South Africa, and a clinical trial of a stem cell-based substitute is expected to begin this fall in the United Kingdom.)

But instead of trying to engineer hemoglobin, Doctor and his colleagues have encased it in a synthetic polymer designed by one of Doctors collaborators, Dipanjan Pan of the University of Illinois, Urbana-Champaign.

They hope the case will ensure that their substitute blood, called ErythroMer, wont cause a tightening in the blood vessels, whichincreases the risk of heart attack and stroke.

At the same time, ErythroMer detects where oxygen should be delivered based on the pH level of the blood, moving oxygen from the lungs to where its most needed like a junkyard magnet picking up a car in one spot and dropping it elsewhere.

If its successful, ErythroMer could be freeze-dried into a powder and stored safely for years, so that when its needed, it can be mixed with sterile water and administered. Its designed to be immune silent so that the immune system doesnt attack it and it could be given to people of any blood type.

Scientists not working on ErythroMer said it appears to be an improvement in some respects over earlier candidates, but note that it is not the first to attempt enclosing hemoglobin in various materials. So far, no one has cracked the code of creating an artificial blood, and its not clear this group will either.

Its not as easy as it sounds, said Dr. Ernest Moore, the vice chair of trauma and critical care research at the University of Colorado, Denver, who has helped run clinical trials of other substitutes.

One concern for Mark Scott, a senior scientist at Canadian Blood Services, is the tininess of ErythroMer. Each particle is about one-fiftieth the size of a normal red blood cell, and Scott said that increased the risk that it could leak from the bloodstream into surrounding tissue. And when someone loses a lot of blood and goes into shock, their blood vessels only become more leaky, Scott said.

Pentagon hopes to use foam, injected through belly button, to save bleeding soldiers

These are all things that you really have to be concerned about, said Scott, who also works at the Center for Blood Research at the University of British Columbia. Is the size going to lead to a lot of vascular leakage? Is the hemoglobin thats inside the shell stabilized so it wont cause acute or chronic toxicity?

One advantage of the small size of the substitute blood, both Scott and Doctor said, is that it could be used for people with sickle cell disease. During sickle cell crises, the misshapen red blood cells gum up blood vessels, and its possible that ErythroMer could get around the logjams and deliver oxygen past those points. Doctor also raised the idea that it could be used to oxygenate organs during transplant operations.

In addition to overcoming the biological hurdles, the ErythroMer team will eventually have to convince regulators that itsproduct is safe enough to test in people (depending on its success in animals, that is). Several scientists said the Food and Drug Administration seems hesitant to green-light new trials of blood substitutes and some said rightfully so because of safety concerns from past products. Plus, clinical trials of trauma-related treatments often run into ethical quandaries about informed consent.

In an email, an FDA spokeswoman said that studies on these types of products have found they are not safe or effective, but that the agency recognizes they potentially could be lifesaving in situations where blood transfusion is necessary, but blood is not available or cant be used. She said future clinical studies remain possible.

Still, human studiesare a long ways away, the researchers acknowledge. So far, Doctor and his team, whose work has been supported by the Department of Defense, have presented results from rodent studies at a scientific conference. And they have their own questions about how ErythroMer will perform as they test it in larger animals, first in rabbits: Does it damage other cells in the bloodstream? Does it interfere with the clotting process?

The team has formed a company called KaloCyte (Greek for good cell) to make the substitute for further studies. Doctor likened it to moving the production from a craft brewery scale so far, Doctor said, its been lovingly made by graduate students, batch by batch to the scale and standards of another St. Louis blend, Budweiser.

Andrew Joseph can be reached at andrew.joseph@statnews.com Follow Andrew on Twitter @DrewQJoseph

Read more:
Artificial blood: the quest for one of science's holy grails - Stat - STAT

Posted in Colorado Stem Cells | Comments Off on Artificial blood: the quest for one of science’s holy grails – Stat – STAT

Stem cell: Knee arthritis in new $33 million research plan – Capitol Weekly

Posted: March 5, 2017 at 9:44 am

News

by DAVID JENSEN posted 03.02.2017

The California stem cell agency this week approved nearly $33 million for clinical stage research projects testing treatments for type 1 diabetes, arthritis of the knee, ALS and an immunodeficiency affliction.

The awards were quickly approved with little discussion during a meeting at the Oakland headquarters of the California Institute for Regenerative Medicine or CIRM, as the agency is formally known.

The goal of the research is to regenerate knee cartilage through the use of a mesenchymal progenitor cell treatment, according to the agencys application review summary

The award likely to have an impact on the most people if it is successful is a relatively small, $2.3 million award to the Cellular Biomedicine Group, a Chinese firm with operations in Cupertino, Calif. The stem cell agency by law only finances work in Clifornia. The research would also be supported by $572,993 in co-funding.

The project is aimed at treating osteoarthritis of the knee. More than 51 million people in the United States suffer from arthritis, which is particularly common in the knee.

The goal of the research is to regenerate knee cartilage through the use of a mesenchymal progenitor cell treatment, according to the agencys application review summary. The funding would go to manufacture the product and complete work to secure Food and Drug Administration approval for a phase one safety trial. A treatment for the public would likely be years in the future.

Here are the other winners today of California stem cell cash with links to the summaries of the reviews.

Caladrius Biosciences of New Jersey won $12.2 million for a clinical trial for young people ages 12-17 for newly diagnosed type 1 diabetes. The firm plans to use regulatory T cells from the patients themselves to treat the disease. Caladrius has a California location in Mountain View. (Caladrius press release can be found here.)

St. Judes Research Hospital in Memphis, Tenn., was awarded $11.9 million for a phase one/two trial to treat infants with X-linked severe combined immunodeficiency. The trial would aim at enrolling at least six patients suffering from the catastrophic affliction. The treatment would use the patients own bone marrow stem cells after the cells were specially handled. The agency said in a press release that St. Judes is working with UC San Francisco. (St. Judes press release can be found here.)

The awards were previously approved behind closed doors by the agencys out-of-state reviewers, who do not disclose publicly their economic or professional interests.

Cedars-Sinai Medical Center in Los Angeles was awarded $6.2 million for a phase 1/2A trial to test a treatment for ALS, which has no treatment or cure. The CIRM review summary said a huge unmet need existed. About 20,000 persons in the United States suffer from the affliction.

CIRMs press release did not identify the researchers involved in any of the awards.

The agency is on a push to support more clinical trials, which are the last and most expensive research prior to the possibility of winning federal approval for widespread use of a therapy.

Currently the agency is participating in 27 trials and is planning on adding 37 more in the next 40 months. The agency is expected to run out of funds for new awards in June 2020 and has no source of future financing.

The awards were previously approved behind closed doors by the agencys out-of-state reviewers, who do not disclose publicly their economic or professional interests. The agencys directors rarely overturn a positive decision by the reviewers.

All of the winners have links to two or more members of the 29-member CIRM governing board. Those members are not allowed to vote on applications where they have conflicts of interest.

About 90 percent of the funds awarded by the board since 2005 have gone to institutions that have ties to members of the board, past or present, according to calculations by the California Stem Cell Report. Eds Note: David Jensen is a retired newsman who has followed the affairs of the $3 billion California stem cell agency since 2005 via his blog, the California Stem Cell Report, where this story first appeared. He has published more than 4,000 items on California stem cell matters in the past 11 years.

Support for Capitol Weekly is Provided by:

Read more:
Stem cell: Knee arthritis in new $33 million research plan - Capitol Weekly

Posted in California Stem Cells | Comments Off on Stem cell: Knee arthritis in new $33 million research plan – Capitol Weekly

Exclusive: CBMG CEO Talks Stem-Cell Therapies, Cancer Treatments, Financials & The Chinese Market – Benzinga

Posted: March 5, 2017 at 9:44 am

Cellular Biomedicine Group Inc (NASDAQ: CBMG) is a micro-cap biomedicine company focused on the development of treatments for cancerous and degenerative diseases through cell-based technologies.

Last week, Benzinga attended SCN Corporate Connects Family Office & Life Science Symposium at the NASDAQ and had the chance to talk with CBMG CEO Tony Liu who walked us through some of the companys products, management team, market potential, how they use stem cells and more.

CBMG has two leading technology platforms at the time, Liu began. One is an immune cell therapy aimed at the treatment of a broad range of cancers using Cancer Vaccines, Chimeric Antigen Receptor T cell (CAR-T) and anti-PD-1 Technologies. The other one uses stem cells for regenerative purposes; the key indication for this therapy is knee osteoarthritis.

Our focus is on these technologies and our market is China, because that is the largest -by far- in population for the indication, he pointed out.

Benzinga: How does the company use stem cells.

Liu: In simple terms, a stem cell is basically regenerative. So a stem cell has the enormous power of expanding, continue from the embryonic stem cell to the baby stem cell and ultimately to the adult stem cell, so it has a great ability to continue to expand and grow.

From the medical perspective, an adult stem cell can regenerate, it can repair [tissue]. So, in our lead product, we use fat tissue from the stomach and we all have a few ounces of extra fat. We take the stem cell out from the fat tissue culture, expand it, and then we inject back in the kneecap for patients with a knee osteoarthritis problem.

Benzinga: Are there any other indications you will be targeting in the near-future?

Liu: Were targeting lymphoma, leukemia, solid tumors and many other areas.

Benzinga moved on to ask about the size of the market.

Liu: Every year we look at 4.5 million to 5 million new cancer patients. That is, every minute we are talking about eight or nine new cancer patients. That is why it is a huge social issue. That is one of the reasons why I choose to stay in the business after I spent 19 years with Microsoft Corporation (NASDAQ: MSFT) and four years with Alibaba Group Holding Ltd (NYSE: BABA). I think this area socially, you want to make impactful, and economically I think there is a huge business from that side.

Because our focus is on the Chinese market there are many investors in the U.S. who do not know us well. However, I believe investors should look at the company: we have a huge market, great scientists, manufacturing space

Then, for our stem cell therapies in China, 57 million people have a knee issue; in the U.S., 27 million [people] have a knee issue. Stem cells can help knees regenerate by doing two things. First, by helping with the pain, providing symptom relief and functional improvements. Secondly, they regenerate the cartilage, which originally caused the knee problem. Nowadays, patients can only opt between pain pills or a knee replacement.

Today, if you do a knee replacement, you are looking at tens of thousands [of dollars]. So, any way you look at it, [its a] multi-billion [market] for knee treatments.

Benzinga: When you say stem cells, people imagine It is a slightly controversial subject; it has some political implications. So, what is the Chinese governments stance regarding stem cells? Are there any risks? Is it accepted? What is the view of stem cells in China?

Liu: Chinas government has been extremely supportive of using stem cells. I think the controversy comes in where people use embryonic stem cells, when you create a new life, that is where the controversy is. But, we use what we call adult stem cells to improve peoples lives, improve their life experiences

On adult stem cells, there is little controversy. The policy of Chinas government is very clear. In fact, in the U.S. it is very clear as well. CBMG has been graced to work with the California Stem Cell Institute. Potentially, we are going to ask the U.S. for large-scale clinical trials.

Our management team was educated in the U.S., and has experience managing large businesses, Liu commented. Our Chief Scientific Officer is a former MedImmune/AstraZeneca plc (ADR) (NYSE: AZN) director. Some of our oncology scientists are from there as well. We also have scientists from the National Cancer Institute. We also have a person who is leading our manufacturing capabilities who worked for Harvard for 30 years and a top German company, leading research for seven years total.

So, we have this kind of people with skills come to China. Our company has 130 people with PhDs, and more than 30 with post-doctorate studies, so there is a lot of brain power, I believe, and we have a common vision that is to create the best, first in class, biotech business in China.

Benzinga: Whats one objective you have as a CEO for 2017?

Liu: In 2017 is about clinical, clinical, clinical. We now have moved our first two indications into the clinical trial stage. We have a lot of patients lined up for clinical trials.

So, as CEO Ill make sure we mobilize all the resources around the clinical trials and make sure we have the lead PI, lead hospitals, and we have resources waiting in the company to make sure we have successful clinical trials. Those are key elements, and we are confident that we should be able to move forward, given the number of patients we have, move schedule, look at the indications

Benzinga: Are you comfortable with your cash and debt position? Do you have any plans to raise capital this year or any time soon?

Liu: One of the benefits we have, CBMG has been regarded as the leader in Chinas cell therapy space, so we have investors who have given us money for the last three years, always at a premium to the market. They know who we are; they know the space we are in. I feel as we move forward, we will be getting more investment needs from trials, and I feel confident investors will look at CBMG as a way for them to both put money into the research, but also, as an investment that could reap great returns.

Benzinga: Your stock had been performing pretty well, but experienced a tumble between mid-November and late-February. What happened there?

Liu: CBMGs stock is really thinly traded. Much of the stock is owned by those who have been with the company for a long time; so, they dont sell. Having said this, there are many reasons that drive stocks: the U.S. election, the pricing discussion Many investors dont discriminate, and just punish biotech as a whole. However, CBMG is not really subject to most of these pricing pressures. In fact, because we have a different cost structure, I expect CBMG to do extremely well.

Image Credit: By Ryddragyn at English Wikipedia - Transferred fromen.wikipediato Commons., Public Domain, via Wikimedia Commons

Posted-In: Biotech News Emerging Markets Health Care Events Exclusives Markets Tech Best of Benzinga

2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read more:
Exclusive: CBMG CEO Talks Stem-Cell Therapies, Cancer Treatments, Financials & The Chinese Market - Benzinga

Posted in California Stem Cells | Comments Off on Exclusive: CBMG CEO Talks Stem-Cell Therapies, Cancer Treatments, Financials & The Chinese Market – Benzinga

Cellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM) – OrthoSpineNews

Posted: March 5, 2017 at 9:44 am

Share this story with your network

SHANGHAI, China and CUPERTINO, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) Cellular Biomedicine Group Inc. (NASDAQ:CBMG)(CBMG or the Company), a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today that the governing Board of the California Institute for Regenerative Medicine (CIRM), Californias stem cell agency, has awarded the Company $2.29 million to support pre-clinical studies of AlloJoinTM, CBMGs Off-the-Shelf Allogeneic Human Adipose-derived Mesenchymal Stem Cells for the treatment of Knee Osteoarthritis in the United States.

While CBMG recently commenced two Phase I human clinical trials in China using CAR-T to treat relapsed/refractory CD19+ B-cell Acute Lymphoblastic Leukemia (ALL) and Refractory Diffuse Large B-cell Lymphoma (DLBCL) as well as an ongoing Phase I trial in China for AlloJoinTM in Knee Osteoarthritis (KOA), this latest announcement represents CBMGs initial entrance into the United States for its off-the-shelf allogeneic stem cell candidate AlloJoinTM.

The $2.29 million was granted under the CIRM 2.0 program, a comprehensive collaborative initiative designed to accelerate the development of stem cell-based treatments for people with unmet medical needs. After the award, CIRM will be a more active partner with its recipients to further increase the likelihood of clinical success and help advance a pre-clinical applicants research along a funding pipeline towards clinical trials. CBMGs KOA pre-clinical program is considered late-stage, and therefore it meets CIRM 2.0s intent to accelerate support for clinical stage development for identified candidates of stem cell treatments that demonstrate scientific excellence.

We are deeply appreciative to CIRM for their support and validation of the therapeutic potential of our KOA therapy, said Tony (Bizuo) Liu, Chief Executive Officer of CBMG. We thank Dr. C. Thomas Vangsness, Jr., in the Department of Orthopaedic Surgery at the Keck School of Medicine of the University of Southern California and Dr. Qing Liu-Michael at the Broad Center for Regenerative Medicine and Stem Cell Research at USC, who helped significantly with the grant application process. The CIRM grant is the first step in bringing our allogeneic human adipose-derived mesenchymal stem cell treatment for knee osteoarthritis (AlloJoinTM) to the U.S. market.

Our AlloJoinTM program has previously undergone extensive manufacturing development and pre-clinical studies and is undergoing a Phase I clinical trial in China. In order to demonstrate comparability with cell banks previously produced in China for our U.S. IND filing, we are addressing the pre-clinical answers required for the FDA. With the funds provided by CIRM, we will replicate and validate the manufacturing process and control system at the cGMP facility located at Childrens Hospital Los Angeles to support the filing of an IND with the FDA. The outcome of this grant will enable us to have qualified final cell products ready to use in a Phase I clinical trial with Dr. Vangsness as the Principal Investigator and the Keck School of Medicine of USC as a trial site. Dr. Vangsness is familiar with both stem cell biology and KOA, and has led the only randomized double-blind human clinical study to investigate expanded allogeneic mesenchymal stem cells to date. Our endeavor in the U.S. market will further strengthen our commercialization pipeline.

CBMG recently announced promising interim 3-month safety data from its Phase I clinical trial in China for AlloJoinTM, its off-the-shelf allogeneic stem cell therapy for KOA. The trial is on schedule to be completed by the third quarter of 2017.

About CIRM

At CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and to act with a sense of urgency commensurate with that mission. To meet this challenge, our team of highly trained and experienced professionals actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of todays most promising stem cell technologies.

With $3 billion in funding and over 280 active stem cell programs in our portfolio, CIRM is the worlds largest institution dedicated to helping people by bringing the future of medicine closer to reality.

For more information, please visit http://www.cirm.ca.gov.

About Knee Osteoarthritis

According to the Foundation for the National Institutes of Health, there are 27 million Americans with Osteoarthritis (OA), and symptomatic Knee Osteoarthritis (KOA) occurs in 13% of persons aged 60 and older. The International Journal of Rheumatic Diseases, 2011 reports that approximately 57 million people in China suffer from KOA. Currently no treatment exists that can effectively preserve knee joint cartilage or slow the progression of KOA. Current common drug-based methods of management, including anti-inflammatory medications (NSAIDs), only relieve symptoms and carry the risk of side effects. Patients with KOA suffer from compromised mobility, leading to sedentary lifestyles; doubling the risk of cardiovascular diseases, diabetes, and obesity; and increasing the risk of all causes of mortality, colon cancer, high blood pressure, osteoporosis, lipid disorders, depression and anxiety. According to the Epidemiology of Rheumatic Disease (Silman AJ, Hochberg MC. Oxford Univ. Press, 1993:257), 53% of patients with KOA will eventually become disabled.

About Cellular Biomedicine Group (CBMG)

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. Our immuno-oncology and stem cell projects are the result of research and development by CBMGs scientists and clinicians from both China and the United States. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. To learn more about CBMG, please visit http://www.cellbiomedgroup.com.

Forward-looking Statements

This press release contains forward-looking statementsincluding descriptions of plans, strategies, trends, specific activities, investments and other non-historical factsas defined by the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently uncertain, and actual results could differ materially from those anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy (including the devaluation of the RMB by China in August 2015), and other risks detailed in CBMGs reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as may, will, expects, plans, intends, estimates, potential, continue or similar terms or their negations. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Read the original post:
Cellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM) - OrthoSpineNews

Posted in California Stem Cells | Comments Off on Cellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM) – OrthoSpineNews

Gene therapy offers hope for newborns with severe immune disorder – University of California

Posted: March 5, 2017 at 9:44 am

Infants born with a type of the devastating immune disorder SCID, or bubble boy disease, may have the option of a novel gene therapy treatment, thanks to a clinical trial atUCSF Benioff Childrens Hospital San Francisco.

The trial is funded by a five-year, $11.9-million grant from theCalifornia Institute for Regenerative Medicine (CIRM)to test technology developed by St. Jude Childrens Research Hospital that delivers a functional gene into the patients blood-producing stem cells. If successful, the gene therapy could provide an alternative to stem cell transplants using donor cells, which can result in serious infection.

The trial expects to treat up to 15 children over the next five years and is open to patients with X-linked severe combined immunodeficiency disease (X-linked SCID), which affects only males. This is the most common form of SCID, which occurs in 1 in every 60,000 newborns, and is caused by defects in the functioning of lymphocytes the white blood cells that are the advanced fighting forces of the immune system. Babies born with SCID appear normal at birth but become sick from infections, skin rashes and failure to gain weight at 3-to-6 months of age. Without a stem cell transplant, they may die before their first birthday.

What is unique about this trial is that the patients own bone marrow stem cells are collected and corrected with the gene therapy, and the corrected cells are then reinfused into the patient, saidMorton Cowan, M.D., of theUCSF Division of Allergy, Immunology, and Blood and Marrow Transplant, and principal investigator of the trial at UCSF.

In stem cell transplants from a donor other than the patient, up to 20 percent of patients with SCID will develop graft-versus-host disease, in which the donor cells attack the recipients tissues. In addition, there is always a risk of the recipient rejecting the donor cells, Cowan said. Using the patients own stem cells means no rejection and no graft-versus-host disease.

The bone marrow transplant program at UCSF is among the largest SCID transplant centers in North America. UCSF pediatric immunologistJennifer Puck, M.D., is known for pioneering the SCID screening method and for nominating SCID to a federal advisory committee for inclusion in the newborn screening panel. Since the screen became available in California in 2010, UCSF has treated more than 30 infants diagnosed with SCID by newborn screening.

UCSF also played an instrumental role in the St. Jude treatment protocol by including a targeted chemotherapy agent, busulfan, along with the gene therapy, which is expected to optimize immune correction. While previous trials have tested gene therapy for this condition, they did not combine it with chemotherapy and had only partial immune correction. Since a low dose of the medication is used, short- and long-term effects are expected to be minimized.

Three patients already have been treated with this lentiviral gene therapy vector two at St. Jude and one at UCSF. The transduction process, in which genetic material is transferred via vector, currently takes place at St. Jude, which freezes the transduced cells and returns them to UCSF for infusion into the patient. The CIRM funding will enable UCSF to begin doing transductions using the St. Jude vector at theUCSF Pediatric Cell Therapy Laboratory, as well as covering the cost of treating patients in the trial.

We believe this trial will not only help us understand more about how lentiviral gene therapy works, but how the use of low-dose busulfan potentially will be effective in treating other non-malignant diseases like sickle-cell anemia, chronic granulomatous disease, marrow failure syndromes and even some cancers in which the patient is too ill to undergo the more toxic traditional treatments, said Cowan.

It will also give us a better idea of what toxicities may be associated with the use of these new vectors, in particular whether they are indeed safer than the older, gamma-retroviral vectors that were associated with a high risk of leukemia, seen in early gene therapy trials for X-linked SCID and other primary immune deficiencies.

More here:
Gene therapy offers hope for newborns with severe immune disorder - University of California

Posted in California Stem Cells | Comments Off on Gene therapy offers hope for newborns with severe immune disorder – University of California

Embryo Experiments Reveal Earliest Human Development, But Stir Ethical Debate – KNAU Arizona Public Radio

Posted: March 5, 2017 at 9:43 am

Ali Brivanlou slides open a glass door at the Rockefeller University in New York to show off his latest experiments probing the mysteries of the human embryo.

"As you can see, all my lab is glass just to make sure there is nothing that happens in some dark rooms that gives people some weird ideas," says Brivanlou, perhaps only half joking.

Brivanlou knows that some of his research makes some people uncomfortable. That's one reason he has agreed to give me a look at what's going on.

His lab and one other discovered how to keep human embryos alive in lab dishes longer than ever before at least 14 days. That has triggered an international debate about a long-standing convention (one that's legally binding in some countries, though not in the U.S.) that prohibits studying human embryos that have developed beyond the two-week stage.

And in other experiments, he's using human stem cells to create entities that resemble certain aspects of primitive embryos. Though Brivanlou doesn't think these "embryoids" would be capable of developing into fully formed embryos, their creation has stirred debate about whether embryoids should be subject to the 14-day rule.

Brivanlou says he welcomes these debates. But he hopes society can reach a consensus to permit his work to continue, so he can answer some of humanity's most fundamental questions.

"If I can provide a glimpse of, 'Where did we come from? What happened to us, for us to get here?' I think that, to me, is a strong enough rationale to continue pushing this," he says.

For decades, scientists thought the longest an embryo could survive outside the womb was only about a week. But Brivanlou's lab, and one in Britain, announced last year in the journals Nature and Nature Cell Biology that they had kept human embryos alive for two weeks for the first time.

That enabled the scientists to study living human embryos at a crucial point in their development, a time when they're usually hidden in a woman's womb.

"Women don't even know they are pregnant at that stage. So it has always been a big black box," Brivanlou says.

Gist Croft, a stem cell biologist in Brivanlou's lab, shows me some samples, starting with one that's 12 days old.

"So you can see this with the naked eye," Croft says, pointing to a dish. "In the middle of this well, if you look down, there's a little white speck it looks like a grain of sand or a piece of dust."

Under a microscope, the embryo looks like a fragile ball of overlapping bubbles shimmering in a silvery light with thin hairlike structures extending from all sides.

Croft and Brivanlou explain that those willowy structures are what embryos would normally extend at this stage to search for a place to implant inside the uterus. Scientists used to think embryos could do that only if they were receiving instructions from the mother's body.

"The amazing thing is that it's doing its thing without any information from mom," Brivanlou says. "It just has all the information already in it. That was mind-blowing to me."

The embryos they managed to keep alive in the lab dish beyond seven days of development have also started secreting hormones and organizing themselves to form the cells needed to create all the tissues and organs in the human body.

The two scientists think studying embryos at this and later stages could lead to discoveries that might point to new ways to stop miscarriages, treat infertility and prevent birth defects.

"The only way to understand what goes wrong is to understand what happens normally, or as normally as we can, so we can prevent all of this," Brivanlou says.

The 14-day cutoff

But Brivanlou isn't keeping these embryos alive longer than 14 days because of the rule.

"The decision about pulling the plug was probably the toughest decision I've made in my scientific career," he says. "It was sad for me."

The 14-day rule was developed decades ago to avoid raising too many ethical questions about experimenting on human embryos.

Two weeks is usually the moment when the central nervous system starts to appear in the embryo in a structure known as the "primitive streak."

It's also roughly the stage at which an embryo can no longer split into twins. The idea behind the rule is, that's when an embryo becomes a unique individual.

But the rule was initiated when no one thought it would ever be possible to keep embryos growing in a lab beyond two weeks. Brivanlou thinks it's time to rethink the 14-day rule.

"This is the moment," he says.

Scientists, bioethicists and others are debating the issue in the U.S., Britain and other countries. The rule is law in Britain and other countries and incorporated into widely followed guidelines in the United States.

Insoo Hyun, a bioethicist at Case Western Reserve University, advocates revisiting the rule. It would allow more research to be done on embryos that are destined to be destroyed anyway, he says embryos donated by couples who have finished infertility treatment.

"Given that it has to be destroyed," Hyun says, "some would argue that it's best to get as much information as possible scientifically from it before you destroy it."

But others find it morally repugnant to use human embryos for research at any stage of their development and argue that lifting the 14-day rule would make matters worse.

"Pushing it beyond 14 days only aggravates what is the primary problem, which is using human life in its earliest stages solely for experimental purposes," says Dr. Daniel Sulmasy, a Georgetown University bioethicist.

The idea of extending the 14-day rule even makes some people who support embryo research queasy, especially without first finding another clear stopping point.

Hank Greely, a Stanford University bioethicist, worries that going beyond 14 days could "really draws into question whether we're using humans or things that are well along the path to humans purely as guinea pigs and purely as experimental animals."

Embryo alternative: "Embryoids"

So as that debate continues, Brivanlou and his colleagues are trying to develop another approach. The scientists are attempting to coax human embryonic stem cells to organize themselves into entities that resemble human embryos. They are also using induced pluripotent stem (iPS) cells, which are cells that behave like embryonic stem cells, but can be made from any cell in the body.

Brivanlou's lab has already shown that these "embryo-like structures" or "embryoids" can create the three fundamental cell types in the human body.

But the scientists have only been able to go so far using flat lab dishes. So the researchers are now trying to grow these embryonic-like structures in three dimensions by placing stem cells in a gel.

"Essentially, we're trying to, in a way, to re-create a human embryo in a dish starting from stem cells," says Mijo Simunovic, another of Brivanlou's colleagues.

In early experiments, Simunovic says, he has been able to get stem cells to "spontaneously" form a ball with a "cavity in its center." That's significant because that's what early human embryos do in the uterus.

Simunovic says it's unclear how close these structures could become to human embryos entities that have the capability to develop into babies.

"At the moment, we don't know. That's something that's very hot for us right now to try to understand," Simunovic says.

Simunovic argues the scientists are not "ethically limited to studying these cells and studying these structures" by the 14-day rule.

There's a debate about that, however.

"At what point is your model of an embryo basically an embryo?" asks Hyun, especially when the model seems to have "almost like this inner, budding life."

"Are we creating life that, in the right circumstances, if you were to transfer this to the womb it would continue its journey?" he asks.

Dr. George Daley, the dean of the Harvard Medical School and a leading stem cell researcher, says scientists have been preparing for the day when stem-cell research might raise such questions.

"I think what prospects people are concerned about are the kinds of dystopian worlds that were written about by Aldous Huxley in Brave New World," Daley says. "Where human reproduction is done on a highly mechanized scale in a petri dish."

Daley stresses scientists are nowhere near that, and may never get there. But science moves quickly. So Daley says it's important scientists move carefully with close ethical scrutiny.

The latest guidelines issued by the International Society for Stem Cell Research call for intensive ethical review, Daley notes.

Brivanlou acknowledges that some of his experiments have produced early signs of the primitive streak. But that's a very long way from being able to develop a spinal cord, or flesh and bones, let alone a brain. He dismisses the notion that the research on embryoids would ever lead to scientists creating humans in a lab dish.

"They will not get up start walking around. I can assure you that," he says, noting that full human embryonic development is a highly complex process that requires just the right mix of the biology, physics, geometry and other factors.

Nevertheless, Brivanlou says all of his experiments go through many layers of review. And he's convinced the research should continue.

"It would be a travesty," he says, "to decide that, somehow, ignorance is bliss."

RACHEL MARTIN, HOST:

Scientists doing embryo research are facing some sensitive questions over a new generation of scientific experiments, questions like how long should scientists be allowed to keep human embryos alive in their labs to study them? And should entities that they create from stem cells resembling human embryos be treated the same way? NPR's health correspondent Rob Stein visited a lab that's at the forefront of this provocative research, and he brings us now the first of two reports.

ROB STEIN, BYLINE: So what are we going to see first?

ALI BRIVANLOU: A human embryo that is attached and grown for 13 days in a petri dish.

STEIN: Ali Brivanlou runs the lab at The Rockefeller University in midtown Manhattan.

So this is an embryo that - where you were able to keep it alive in the laboratory...

BRIVANLOU: Exactly.

STEIN: ...Up until day...

BRIVANLOU: Day 13.

STEIN: And had it been done before?

BRIVANLOU: Never.

STEIN: For decades, scientists thought the longest an embryo could survive outside the womb was only about half that long - only about a week tops. So this is the first time scientists can actually see living human embryos at this crucial stage of development and study them at a time when they're usually hidden in a woman's womb.

BRIVANLOU: And women don't even know they are pregnant at that stage, so it has always been a big black box.

STEIN: Brivanlou arranged for one of his colleagues to show me.

BRIVANLOU: I ask him to make sure that he has a real sample for you to see with your own eyes so that you can appreciate the beauty in their own glory. It's really one of the most beautiful things I have ever seen in my life.

STEIN: Brivanlou's colleague Gist Croft pulls out some samples. Turns out, he's going to show me several embryos, starting with one that's 12 days old.

GIST CROFT: So you can see this with the naked eye. In the middle of this well, if you look down, there's a little white speck that looks like a grain of sand or a piece of dust in this well right here. I don't know if you can - can you see that?

STEIN: Yeah, it looks like a tiny little white translucent dot.

CROFT: That's it.

STEIN: Croft carefully places it on a big microscope and pulls a heavy black curtain closed.

CROFT: Would you like to look through the microscope?

STEIN: Yeah.

BRIVANLOU: OK.

STEIN: Croft helps me bring the embryo into focus.

Oh, yeah, I can see...

CROFT: Better?

STEIN: I can see the - oh, wow. Wow, that's, like, kind of beautiful.

It is quite stunning. It looks like a fragile ball of overlapping bubbles that's sort of shimmering in a silvery light, but it's also a little, well, funny looking.

So that looks like a (laughter) well, I mean, it kind of just looks like a - kind of a translucent hairy ball actually.

CROFT: Yes.

STEIN: Croft and Brivanlou get excited that I noticed what looked like little hairs reaching out from all sides because that's exactly what scientists would expect embryos to do at this stage if they were in the womb - search for just the right spot to nestle in.

CROFT: They're doing the reaching out and attaching that they normally do into uterus cells, but here they're doing it onto plastic.

STEIN: Wow, so they're behaving like they would - this embryo is behaving like it would if it was actually in the womb.

CROFT: That's right. It's reproducing certain key features of what it's normally doing in the womb.

STEIN: Scientists thought embryos could only do that sort of thing if they were getting instructions from their mother's body about what to do next - not all alone in some plastic dish.

BRIVANLOU: The amazing thing is that it's doing its thing without any information from mom - completely unexpected to me. It just has all the information already in it. That was mind-blowing to me.

STEIN: The embryos also start pumping out hormones and start organizing themselves, all by themselves, to form the cells needed to create all the tissues and organs that make up the human body. So Brivanlou and his colleagues think they could learn lots of things by studying them that could help stop miscarriages, treat infertility, prevent birth defects.

BRIVANLOU: The only way to understand what goes wrong is to understand what happens normally or as normally as we can so we can prevent all of this.

STEIN: But that would mean studying embryos beyond 14 days and Brivanlou can't keep these embryos alive any longer to keep studying them. Why? Because of a rule that says scientists should not conduct experiments on human embryos that are more than 14 days old. So Brivanlou decided he had no choice but to pull the plug on these experiments.

BRIVANLOU: The decision about pulling the plug was probably the toughest decision I've made in my scientific career. It was sad for me. It was sad.

STEIN: The 14-day rule was adopted decades ago to avoid raising too many ethical questions. It's a guideline in the U.S. but law in some other countries. Fourteen days is when the central nervous system starts forming, starting with something called the primitive streak. It's also usually when an embryo can't split into twins anymore. So the idea is that's when it truly becomes an individual. But that was before anyone thought it would ever be possible to go beyond two weeks. So Brivanlou says it's time to rethink the 14-day rule.

BRIVANLOU: It's time to reopen that debate. This is the moment. I think we are here. It would be a travesty to decide that somehow ignorance is bliss.

STEIN: And Brivanlou's not alone. There's a big debate about this going on in the United States, Britain and other countries. Insoo Hyun is a bioethicist at the Case Western Reserve University. He points out that these are embryos that were donated for research by couples who were finished with infertility treatments.

INSOO HYUN: You have to realize that with these embryos they are being used for research. That decision has been made. Now, the question is how long can you study them before they have to be destroyed? So given that it has to be destroyed, some would argue that it's best to get as much information as possible scientifically from it before you destroy it.

STEIN: Now, some people think it's morally repugnant to use human embryos for any kind of research at any stage of their development. And lifting the 14-day rule, that would just make matters worse. But the idea of extending the 14-day rule even makes some people who support embryo research uncomfortable, especially without first coming up with another clear stopping point. Hank Greely is a bioethicist at Stanford.

HANK GREELY: Unless there was something really important we could learn from doing research with human embryos, I wouldn't allow research beyond 14 days because at some point experimentation with it seems to really draw into question whether we're using humans or things that are well along the path to humans purely as guinea pigs and purely as experimental animals.

STEIN: So as that debate continues, Brivanlou and his colleagues are trying something else. They're using stem cells to create things that resemble primitive human embryos in their lab, but that's controversial too. Rob Stein, NPR News, New York.

View post:
Embryo Experiments Reveal Earliest Human Development, But Stir Ethical Debate - KNAU Arizona Public Radio

Posted in Arizona Stem Cells | Comments Off on Embryo Experiments Reveal Earliest Human Development, But Stir Ethical Debate – KNAU Arizona Public Radio

Interviews for UA President Monday; Announcement Wednesday – Arizona Public Media

Posted: March 5, 2017 at 9:43 am

The two finalists for president of the University of Arizona will interview with the Board of Regents in private sessions Monday, followed by a Tuesday private session to select the top candidate.

The decision will be announced at a Tuesday press conference, the regents said in a press release. That candidate will meet the community at a public forum Wednesday on campus.

"The finalist will have an opportunity to meet with students, faculty, staff and members of the public during a moderated question and answer session," the regents' press release said.

Interviewing for the job Monday will be Sethuraman Panch Panchanathan, executive vice president and chief research and innovation officer at Arizona State University, and Robert Clayton Robbins, president and chief executive officer at the Texas Medical Center.

The board is seeking a replacement for Ann Weaver Hart, who announced last year she will not seek renewal of her contract past its 2018 expiration. The regents have said Hart will step down once a new president is ready to come on board, anticipated by this summer.

The press release said the regents hope to meet March 13 to finalize their selection, followed by contract negotiations and a final agreement to be voted on and announced at an April 6 regents' meeting.

Panchanathan is responsible for advancing research, innovation, entrepreneurship and economic development at ASU. During his tenure, ASU has been ranked by U.S. News & World Report as No. 1 on its Most Innovative Schools list for two consecutive years.

He is a computing and informatics expert and is director of the center for "cognitive ubiquitous computing." He was founding director of the ASU School of Computing and Informatics and was instrumental in founding the Biomedical Informatics Department at ASU.

Robbins is a cardiac surgeon who joined the Texas Medical Center as its president and CEO in 2012. In that time, he introduced research initiatives on innovation, genomics, regenerative medicine, health policy and clinical research. The Texas Medical Center is the largest medical complex in the world, the press release said.

As a surgeon, Robbins has focused on acquired cardiac diseases with a special expertise in the surgical treatment of congestive heart failure and cardiothoracic transplants. His research work includes the investigation of stem cells for cardiac regeneration.

The regents used a search firm to find candidates for the position, and news media reports said two internal candidates were among those considered. They were identified as UA Provost and Senior Vice President for Academic Affairs Andrew C. Comrie and Joaquin Ruiz, vice president for innovation and dean of the UA College of Science.

Hart became UA president in July 2012, the first woman in the position. She came from Temple University in Philadelphia, where she was president, and before that, was president of the University of New Hampshire.

Under agreement with the Board of Regents, Hart will retain her salary of $475,000 a year, take a one-year leave of absence upon stepping down as university president and will be a professor in the College of Education when she returns.

The rest is here:
Interviews for UA President Monday; Announcement Wednesday - Arizona Public Media

Posted in Arizona Stem Cells | Comments Off on Interviews for UA President Monday; Announcement Wednesday – Arizona Public Media

Department of Cell Biology and Physiology, School of …

Posted: March 5, 2017 at 9:41 am

Message From Our Chair

Welcome to the Department of Cell Biology and Physiology in the School of Medicine at the University of North Carolina at Chapel Hill where our mission is to be nationally recognized for excellence in our discipline by Leading, Teaching and Caring.

LeadingWe conduct cutting-edge, innovative research that advances the discipline of cell biology and physiology, with an emphasis on topics that contribute to the improvement of human health. The UNC-CH Department of Cell Biology and Physiology is nationally-recognized and ranked #2 in the country for our level of NIH funding in 2016! The Department comprises over 35 basic science laboratories dedicated to integrative research in areas related to neuroscience, cardiovascular development and disease, cell motility, cellular cytoskeleton and intracellular trafficking, gastrointestinal biology, cellular mechanisms of aging and cancer biology. I encourage you to browse our website, which highlights each individual faculty research program. Our faculty, trainees and staff benefit from robust partnerships with numerous Centers across campus including the Lineberger Comprehensive Cancer Center, McAllister Heart Institute, Marsico Lung Institute and Thurston Arthritis Research Center, to name a few.

TeachingWe provide a rigorous and competitive educational experience for a diverse population of graduate and professional trainees which enables them to succeed in their future careers. The Department has a long tradition of successfully training the next generation of scientists. Our newly-launched Curriculum in Cell Biology and Physiology offers an integrated training program for PhD students. In addition, the Department is home to a multitude of undergraduate, medical and clinical fellow trainees who are seeking avenues for intellectually-engaging and creative research experiences. Research scientists who train in the discipline of cell biology and physiology will benefit from being able to synergize their training from several vantage points. For example, the development of sophisticated genetic engineering tools enables us to test focused hypotheses on the multi-cellular diversity of organs and their cellular compositions. Likewise, these same genetic techniques, coupled with the ability to image cell behavior at unprecedented resolution and the application of -omics approaches, permits a broader exploration into how cells sense and respond to their environments, either within an organ or in response to different pathophysiological conditions. In these ways, research trainees in our Department can capitalize on rapid technological advances and successfully apply their findings to inform the fundamental processes of normal and pathological physiology and cell biological behaviors.

CaringWe serve the people of North Carolina, the United States and the international community, by excelling in our research and educational missions thereby promoting the health and well-being of individuals and communities locally, nationally and internationally. The Department of Cell Biology and Physiology has a strong commitment to fostering an environment of inclusion, diversity and wellness within the workplace, which lays the foundation for collaborative partnerships and creative exploration. We provide award-wining mentoring and professional development activities for individuals at all career stages. Our faculty and trainees actively participate in local and national service, giving back to our communities.

It is an exciting time for the Department, with six new faculty hires, the launch of our state-of-the-art Hooker Imaging Core Facility and remarkable accolades and recognition of our distinguished faculty and trainees. I hope that you will enjoy exploring our research and educational programs, and encourage you to contact us if you would like to join and support our missions.

Read more:
Department of Cell Biology and Physiology, School of ...

Posted in Cell Medicine | Comments Off on Department of Cell Biology and Physiology, School of …

Opinion/Commentary: Global stem cell therapy market to showcase growth – The Daily Progress

Posted: March 5, 2017 at 9:41 am

LONDON Technavio analysts forecast the global stem cell therapy market to grow at a compound annual growth rate of close to 37 percent during the forecast period, according to their latest report.

The research study covers the present scenario and growth prospects of the global stem cell therapy market for 2017-2021. To determine the market size, the study considers revenue generated from allogenic and autogenic stem cell therapies.

The Americas are the largest regional segment of the global stem cell therapy market, responsible for generating over 56 percent of the total revenue (2016 figures). The region is expected to continue market dominance through the forecast period, driven by increasing demand for stem cell therapy products and investments into R&D.

Technavio analysts highlight the following factors as contributing to the growth of the global stem cell therapy market:

Increase in federal funding in stem cell therapy.

Sapna Jha, one of the lead research analysts at Technavio for medical imaging research, says, Many stem cell research institutes and small companies are involved in cutting-edge R&D and are yielding encouraging results. These institutions are witnessing an increased flow of investments from federal organizations, due to the realization of the importance of regenerative medicine.

The U.S. National Institutes of Health, a major funding government organization invested approximately USD 1.5 billion in stem cell research projects in 2016. Similarly, several state-level organizations such as California Institute for Regenerative Medicine has contributed USD 3 billion to stem cell research in 2014. Such funding will help various research institutes to discover and develop regenerative medicines, which will boost the global regenerative medicine market enormously.

Growing demand for personalized medicine.

The health care sector is creating a high demand for personalized medicine, which could offer game-changing opportunities for the vendors. These medicines offer treatments based on the individual characteristics, needs, and preferences, which will vastly improve the quality of health care. Individuals are increasingly banking their stem cells for future treatments. Research organizations are also extensively exploring ways to develop personalized treatments with stem cells, which could eventually erase the conventional medicine system and help in the effective treatment of various diseases such as diabetes and cancer.

Demand for development of effective drugs for cardiology and degenerative disorders.

There has been an increased demand to develop effective drugs for cardiology and degenerative disorders, for which there were no effective treatment plans before the advent of stem therapies. The discovery of possible cardiac stem cells uncovered new arenas to repair hearts injured due to acute myocardial infarction or coronary artery disease, says Sapna.

Researchers are studying and developing approximately 19 product candidates for the treatment of cardiac disorders, with eight of them in Phase III, and six in Phase II.

Technavio is a global technology research and advisory company. This report was made available through The Associated Press.

Visit link:
Opinion/Commentary: Global stem cell therapy market to showcase growth - The Daily Progress

Posted in Cell Therapy | Comments Off on Opinion/Commentary: Global stem cell therapy market to showcase growth – The Daily Progress

Diabetes prevention help offered – Burlington Times News

Posted: March 5, 2017 at 9:40 am

Kyle Lubinsky / Times-News

Alamance Regional Medical Center has partnered with the county health department to teach a class directed toward diabetes prevention in nine area counties.

Diabetes affects a startling number of people in the United States: Nearly 30 million Americans have it.

In North Carolina, its about 1,075,855, roughly 13.1 percent of the adult population. An additional 2.6 million, or 36.1 percent of adults, have pre-diabetes, which means they have high blood glucose levels that arent quite high enough to be diagnosed as diabetes.

We hear it all the time, that we have to eat right and exercise, said Rachel Marquez, master trainer for the diabetes program. However, its about small, sustainable life changes.

The class started in 2015, and so far has seen six groups complete the year-long program. Each program is open to people who are pre-diabetic, and each section is limited to 15 people, although Marquez says she usually averages seven to eight at any given time.

Initially, the program was held at Blessed Sacrament Church. After seeing positive results, the hospital decided to open a class to employees at ARMC. The current class, which graduated Feb. 16, consisted of 14 participants who lost an average of 5.5 percent of their body weight. That reduces individual chances of developing diabetes by 50 to 70 percent.

Marquez has seen a wide variety of participants with a wide variety of motives for taking the class everything from wanting to play with their grandchildren to wanting to get off of their medication. The class has given many of those involved results: Marquez has noticed weight loss and a general decrease in pain in participants at the end of the year.

Rick Settle is one such participant. The registered phlebotomist goes out into the local community around the hospital and tests blood for syphilis and hepatitis C. Over the past few years, his hemoglobin A1C test, which is used to determine whether an adult is diabetic, revealed that he was pre-diabetic. When the program was opened to employees, he ran into Marquez, who encouraged him to join.

Over the next year, Settle lost 43 pounds, and his A1C levels when back down to a healthy number. The positive atmosphere in the class helped him to push through tough times it felt as if everyone was working toward a common goal.

The best part was the encouragement, Settle said. It wasnt as much a competition as it was encouragement. The pounds came off when I watched what I was eating.

The class encouraged Settle and other participants to count their fat grams as they are the most important part of losing weight and keeping it off. It also helped him to form good habits, and the knee problems he had when starting the program have lessened as well.

The main benefit that I saw was a result of the weight loss, he said. As long as I can keep this going, I wont have to take any medication.

Excerpt from:
Diabetes prevention help offered - Burlington Times News

Posted in Diabetes | Comments Off on Diabetes prevention help offered – Burlington Times News

Page 1,652«..1020..1,6511,6521,6531,654..1,6601,670..»